1 asset in Thymic Neuroendocrine Tumor
Therapeutic assets addressing Thymic Neuroendocrine Tumor, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Cabozantinib Thymic Neuroendocrine Tumor | National Cancer Institute (NCI) | P3 | NR () |